Evidence map›Paper›PMID 35746974›Full record

ArticleIBRO neuroscience reports2022

Depression in Sub-Saharan Africa.

Ismail Temitayo Gbadamosi, Isaac Tabiri Henneh, Oritoke Modupe Aluko, Emmanuel Olusola Yawson, Aliance Romain Fokoua, Awo Koomson, Joseph Torbi, Samson Ehindero Olorunnado, Folashade Susan Lewu, Yusuf Yusha'u and 3 more

Open access · goldAbstract read
In one paragraph

Article in IBRO neuroscience reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 50 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
50citing papers in PubMed, 3 pooled it
18.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

50 citing papers in PubMed, 3 syntheses or guidelines pooled it, 100 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 8 institutions in 3 countries.

Ismail Temitayo GbadamosiDepartment of Anatomy, University of Ilorin, Nigeria.
Isaac Tabiri HennehDepartment of Pharmacotherapeutics and Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of Cape Coast, Ghana.
Oritoke Modupe AlukoDepartment of Physiology, School of Basic Medical Sciences, Federal University of Technology, Akure, Nigeria.
Emmanuel Olusola YawsonDepartment of Anatomy Redeemer's University, Nigeria.
Aliance Romain FokouaDepartment of Animal Biology University of Dschang, Cameroon.
Awo KoomsonDepartment of Pharmacology and Toxicology University of Ghana, Ghana.
Joseph TorbiDepartment of Pharmacology and Toxicology University of Ghana, Ghana.
Samson Ehindero OlorunnadoDepartment of Anatomy, Kogi State University, Nigeria.
Folashade Susan LewuDepartment of Anatomy, University of Ilorin, Nigeria.
Yusuf Yusha'uDepartment of Human Physiology Ahmadu Bello University, Zaria, Nigeria.
Salmat Temilola Keji-TaofikDepartment of Anatomy, University of Ilorin, Nigeria.
Robert Peter BineyDepartment of Pharmacotherapeutics and Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, University of Cape Coast, Ghana.
Thomas Amatey TagoePhysiology Department, University of Ghana, Ghana.
University of Ghana · GHUniversity of Ilorin · NGUniversity of Cape Coast · GHAhmadu Bello University · NGFederal University of Technology · NGKogi State University · NGRedeemer's University · NGUniversité de Dschang · CM

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mood disorders can be considered among the most common and debilitating mental disorders. Major depression, as an example of mood disorders, is known to severely reduce the quality of life as well as psychosocial functioning of those affected. Its impact on the burden of disease worldwide has been enormous, with the World Health Organisation projecting depression to be the leading cause of mental illness by 2030. Despite several studies on the subject, little has been done to contextualise the condition in Africa, coupled with the fact that there is still much to be understood on the subject. This review attempts to shed more light on the prevalence of depression in Sub-Saharan Africa (SSA), its pathophysiology, risk factors, diagnosis and the experimental models available to study depression within the sub-region. It also evaluates the contribution of the sub-region to the global research output of depression as well as bottlenecks associated with full exploitation of the sub region's resources to manage the disorder.

Indexed as

AntidepressantsMajor depressive disorderMedicinal plantsSub-Saharan Africa

Identifiers

PMID35746974
PMCPMC9210463
OpenAlexW4220804984

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.